Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

20141,302 citationsJournal Article

Authors

Nezam H. Afdhal · The University of Texas Health Science Center at San Antonio

K. Rajender Reddy · University of Pennsylvania

David R. Nelson · University of Florida

Eric Lawitz · Texas Liver Institute

Stuart C. Gordon · Henry Ford Health System

Eugene R. Schiff · University of Miami

Ronald Nahass

Abstract

Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologic response to prior interferon-based treatment. (Funded by Gilead Sciences; ION-2 ClinicalTrials.gov number, NCT01768286.).

Topics & Keywords

Hepatitis C virus research HIV/AIDS drug development and treatment Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 16, pp. 1483-1493

DOI: 10.1056/nejmoa1316366

Field-Weighted Citation Impact: 131.79